Interleukin Genetics (ILIU) 0.1050 $ILIU Interleukin

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Interleukin Genetics (ILIU) 0.1050 $ILIU

Interleukin Genetics Reports First Quarter 2016 Financial Results
GlobeNewswire - Mon May 16, 7:00AM CDT
Two Agreements Year to Date to Incorporate PerioPredict into Employee Benefit Plans

Interleukin Genetics Announces Conference Call to Discuss First Quarter 2016 Financial Results
GlobeNewswire - Tue May 10, 8:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and webcast on Monday, May 16, 2016, at 8:30 a.m. Eastern Time to provide a corporate update and discuss the Company's first quarter ended March 31, 2016 financial results.

Four Top Stocks to Watch on Wednesday May 4th 2016
ACCESSWIRE - Wed May 04, 11:03AM CDT
MIAMI, FL / ACCESSWIRE / May 4, 2016 / Tech Stock Insider is issuing a report on four stocks to watch. EBIO, LCLP, XGTI, and MJNA have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks, subscribe to our newsletter at TechStockInsider.com.
EBIO: 3.08 (+0.39), XGTI: 0.47 (-0.01)

Genetic Stratification of Drug Response in IL-1 Implicated Eye Diseases
GlobeNewswire - Wed May 04, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, announced today that Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, presented new data from post hoc analyses on the influence of Interleukin's IL-1 genetic patterns on response to isunakinra (EBI-005) in severe allergic conjunctivitis and severe dry eye study subjects. The data were presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, Washington.
EBIO: 3.08 (+0.39)

Interleukin Genetics Receives Notice of Allowance for United States Patent for PerioPredict(R) Genetic Risk Test
GlobeNewswire - Tue Apr 26, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced that it has received a notice of allowance for a patent by the United States Patent and Trademark Office (USPTO) for an application covering the Company's PerioPredict Genetic Risk Test. The application, entitled "Method for Determining Severity and Progression of Periodontal Disease," has allowed claims covering methods of determining a subject's genotype to ascertain their risk of developing severe periodontal disease and the treatment of those at risk to slow the progression of the disease.

PerioPredict(R) Genetic Risk Test Incorporated into Freedom Dental Plan
GlobeNewswire - Thu Apr 21, 7:03AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced it has signed an agreement with Reimbursement Specialists, Inc., a Comprehensive Benefit Administrators (CBA) company and leading provider of benefits management services, to include coverage for Interleukin's PerioPredict Genetic Risk Test as part of CBA's Freedom Dental Plan.

Interleukin Genetics Announces Clarification of Commercial Test Compliance
GlobeNewswire - Tue Apr 05, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases and health-related conditions, today announced the results of discussions with the U.S. Food and Drug Administration (FDA) in response to an Untitled Letter issued by the FDA on November 4, 2015 and a meeting on February 3, 2016 with personnel within FDA's Office of In Vitro Diagnostics and Radiological Health (OIR) to discuss Interleukin's written response to OIR with respect to the Untitled Letter. Interleukin believes it has maintained a constructive relationship with the FDA over many years and is committed to maintaining regulatory compliance for all of its tests.

Interleukin Genetics Reports Fourth Quarter and Year-End 2015 Financial Results
GlobeNewswire - Thu Mar 17, 7:00AM CDT
Progress in Executing Commercial Plan Underscored by

Interleukin Genetics Appoints Global Clinical Advisory Board To Guide Enhanced Healthcare through Targeted Management of Systemic Inflammation
GlobeNewswire - Wed Mar 16, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU), a life sciences company focused on developing and marketing proprietary genetic tests for chronic diseases that reduce longevity and life quality, today announced the appointment of leading experts to its newly formed Clinical Advisory Board to advise the Company on clinical programs aimed at demonstrating the clinical and health economic benefits of targeted prevention and treatment of periodontitis, a common local inflammatory disease, in the management of several chronic diseases that affect widespread tissues and organs of the body.

Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter and Year-End 2015 Financial Results
GlobeNewswire - Tue Mar 15, 8:48AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and webcast on Thursday, March 17, 2016, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company's fourth quarter and year-end 2015 financial results.

Interleukin Genetics Reports Third Quarter 2015 Financial Results
GlobeNewswire - Thu Nov 12, 4:25PM CST
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced financial and operational results for its fiscal third quarter of 2015, ended September 30, 2015.

Interleukin Genetics Reports Second Quarter 2015 Financial Results
BusinessWire - Fri Aug 14, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced financial and operational results for its fiscal second quarter of 2015, ended June 30, 2015.

Interleukin Genetics Announces Conference Call to Discuss Second Quarter 2015 Financial Results
BusinessWire - Fri Aug 07, 6:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) announced today that it will host a conference call and webcast on Friday, August 14, 2015, at 8:30 a.m. (ET), to provide a corporate update and discuss the Company's second quarter 2015 financial results. To access the live call, please dial 877-324-1976 (domestic) or 631-291-4550 (international). The live webcast will also be available at the Investors section of the Company's website at www.ilgenetics.com. The webcast will be archived following the call at www.ilgenetics.com.

Interleukin Genetics to Present at 2015 Marcum MicroCap Conference
BusinessWire - Tue May 19, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced that Mark B. Carbeau, Chief Executive Officer of Interleukin Genetics, will present at the 2015 Marcum MicroCap Conference on Wednesday, May 27, 2015, at 2:30 p.m. (ET) at the Grand Hyatt New York in New York City.

Interleukin Genetics Granted Key European Patent Covering Inherent Health(R) Weight Management Genetic Test
BusinessWire - Wed Apr 15, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced that it has been granted a patent by the European Patent Office (EPO) covering the Company's Inherent Health(R) Weight Management Genetic Test. The granted patent, entitled "Genetic Markers for Weight Management and Methods of Use Thereof," has claims covering methods of determining a subject's metabolic genotype and methods for selecting an appropriate therapeutic/dietary regimen or lifestyle recommendation based on the subject's metabolic profile and susceptibility to adverse weight management issues. The European patent grants coverage of the Weight Management Genetic Test into 2029. Corresponding patents have been granted in major markets throughout the world including Eurasia, Japan, Mexico, Russia and New Zealand, and patent applications are pending in the U.S. and other major markets.

Interleukin Genetics Appoints Mark B. Carbeau as CEO
BusinessWire - Tue Apr 07, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced the appointment of Mark B. Carbeau as Chief Executive Officer and Director. Dr. Kenneth S. Kornman, DDS, PhD, who served as the President and CEO since August 2012, will continue to serve as President, Chief Scientific Officer and a Director.

Interleukin Genetics Collaborators Present Scientific Research Supporting Weight Management Genetic Test at the 2015 Experimental Biology Annual Meeting
GlobeNewswire - Wed Apr 01, 10:50AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) today announced two late-breaking poster presentations supporting its Inherent Health(R) Weight Management Genetic Test at the 2015 Experimental Biology Annual Meeting taking place March 28 - April 1, 2015, in Boston.

Interleukin Genetics and Employee Benefit Consulting Group LLC Partner to Expand Awareness and Adoption of PerioPredict(R)
BusinessWire - Mon Mar 30, 7:00AM CDT
Interleukin Genetics, Inc. (OTCQB:ILIU) and Employee Benefit Consulting Group LLC (EBCG) announced today the signing of a collaboration agreement to help expand knowledge and potential coverage for Interleukin's novel genetic risk test, PerioPredict(R). PerioPredict(R) is an innovative, easy-to-use tool that identifies individuals with a higher risk of progressing to severe periodontal disease.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 87

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
YYForce's Strategic Play: Robotics and AI Expansion

Updated Category News Views 84

Innovation Meets Pragmatism at YYForce There's a new bout of excitement brewing over at YYForce Inc. (NASDAQ: YFOR), if the latest announcements are anything to go by. The Singapore-based AI-enabled workforce dynamo is laying out priorities like a general plotting a campaign—pragmatic, strategic, and with a keen eye on the bottom line. Aiming for a Technological Edge In...

Continue Reading
IQSTEL's Nine-Month Revenue Hits $313M, Growth Impresses

Updated Category News Views 170

Pushing Through With Persistence Well, well, well, here we are, talking about IQSTEL Inc. (NASDAQ: IQST) slinging some serious numbers—not the kind you can ignore at your breakfast table. The company pulled in a whopping $313 million in revenue over the first nine months of 2026. That’s a bump up by 34.5% from last year’s $232.7 million. What’s behind the magic...

Continue Reading
Rock Tech Uncovers Major Lithium Discovery at Victory

Updated Category News Views 84

Rock Tech's Game-Changer at Victory Folks, we've got a shake-up in the lithium landscape over in Ontario, courtesy of Rock Tech Lithium Inc. They just unearthed something quite promising at their Victory Project: a spanking new spodumene-bearing pegmatite discovery. Now I know, if you're like me, you're thinking, 'What's the angle here?' Well, this isn't just another hole...

Continue Reading
TCL Unveils Black Friday Steals on Smart Devices

Updated Category News Views 128

TCL's Big Move This Holiday Season When was the last time you saw a deal that actually made you stop and check your wallet? Well, TCL is giving you a reason to dig deep this Black Friday and Cyber Monday. They're slashing prices across smartphones and tablets, trying to elbow their way into your shopping cart with discounts up to $150. Now that's the kind of aggressive...

Continue Reading
Zettia R. Barnes: Charting a Path in Home Healthcare

Updated Category News Views 146

The Lifeline of Home Healthcare in DeSoto You know, it ain't every day that someone like Zettia R. Barnes steps up in the realm of home healthcare and makes a mark that genuinely sticks. From rubbing shoulders with patients to steering a whole dang organization like Angels of Hands Home Health Agency Corp., she's got her hands full—and frankly, it’s folks like her who...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 98

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 64

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 96

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 94

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading